Clarify Medical plans online direct-to-patient launch after FDA clearance
Jim Sweeney · 641: He Has $25B In Medical Tech Exits, $2B Raised, He's Sitting On PhotoTherapy $1b+ Bet Now with CEO Jim Sweeney · Apr 26, 2017 · at 3:15
Jim Sweeney, CEO of Clarify Medical, outlines the company's timeline for FDA clearance and its commercialization strategy for connected at-home phototherapy devices.
0:00 / 0:23exact quote · 23.2s
720p mp4 · rendered on demand · StarZero watermark
“We've developed a device and are seeking FDA clearance in the next few months. That will enable people to self-treat at home. Using a smart app, we're able to surveil what they're doing, prevent them from over-utilizing a device, communicate all of that information directly to the physician. So we'll be launching this product via the internet directly to patients as soon as we receive FDA clearance.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jim Sweeney
Sweeney: Out-of-pocket costs will force healthcare to treat patients as customers
“The bad news is that people are going to have to start reaching in their pocket to pay for things much more than they ever envisioned in the past. And the good news is as a result of that, they're starting to be viewed for the first time since Medicare was pas…”
Sweeney: Founded healthcare companies have generated over $25B in exit value
“A little north of twenty-five billion.”
Sweeney: Alternative biologic and therapeutic drugs cost up to $100k annually
“Up to a 100,000 dollars a year with biologic and therapeutic drugs that also have horrific side effects.”
Sweeney: Medical tech companies typically exit at 15 to 20x EBITDA
“And these companies exit values would typically be 15 to 20 times EBITDA.”